S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
NASDAQ:ABIO

ARCA biopharma Stock Forecast, Price & News

$1.98
-0.04 (-1.98%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.97
$2.04
50-Day Range
$1.98
$2.61
52-Week Range
$1.97
$5.50
Volume
93,184 shs
Average Volume
170,289 shs
Market Capitalization
$28.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.47
30 days | 90 days | 365 days | Advanced Chart
Receive ABIO News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.


ARCA biopharma logo

About ARCA biopharma

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ABIO
Employees
13
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$4.87 per share

Profitability

Net Income
$-9.74 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,341,000
Market Cap
$28.53 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/02/2021
Today
1/19/2022
Next Earnings (Estimated)
3/17/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.28 out of 5 stars

Medical Sector

1175th out of 1,414 stocks

Diagnostic Substances Industry

19th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












ARCA biopharma (NASDAQ:ABIO) Frequently Asked Questions

How has ARCA biopharma's stock been impacted by COVID-19?

ARCA biopharma's stock was trading at $3.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABIO shares have decreased by 41.1% and is now trading at $1.98.
View which stocks have been most impacted by COVID-19
.

Are investors shorting ARCA biopharma?

ARCA biopharma saw a decrease in short interest in December. As of December 15th, there was short interest totaling 368,200 shares, a decrease of 26.3% from the November 30th total of 499,700 shares. Based on an average trading volume of 434,700 shares, the short-interest ratio is currently 0.8 days. Currently, 2.6% of the shares of the company are short sold.
View ARCA biopharma's Short Interest
.

When is ARCA biopharma's next earnings date?

ARCA biopharma is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for ARCA biopharma
.

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) issued its quarterly earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter.
View ARCA biopharma's earnings history
.

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the following people:
  • Michael R. Bristow, President, Chief Executive Officer & Director
  • Thomas A. Keuer, Chief Operating Officer
  • C. Jeffrey Dekker, Chief Financial Officer
  • Debra Marshall, Chief Medical Officer
  • Christopher David Ozeroff, Secretary, Senior Vice President & General Counsel

What is Michael R. Bristow's approval rating as ARCA biopharma's CEO?

1 employees have rated ARCA biopharma CEO Michael R. Bristow on Glassdoor.com. Michael R. Bristow has an approval rating of 100% among ARCA biopharma's employees. This puts Michael R. Bristow in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ARCA biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ARCA biopharma investors own include Aurora Cannabis (ACBFF), MannKind (MNKD), Bausch Health Companies (BHC), Biocept (BIOC), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Gilead Sciences (GILD), iBio (IBIO), Nabriva Therapeutics (NBRV) and Synergy Pharmaceuticals (SGYP).

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How do I buy shares of ARCA biopharma?

Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ARCA biopharma's stock price today?

One share of ABIO stock can currently be purchased for approximately $1.98.

How much money does ARCA biopharma make?

ARCA biopharma has a market capitalization of $28.53 million. The biopharmaceutical company earns $-9.74 million in net income (profit) each year or ($1.61) on an earnings per share basis.

How many employees does ARCA biopharma have?

ARCA biopharma employs 13 workers across the globe.

What is ARCA biopharma's official website?

The official website for ARCA biopharma is arcabio.com.

Where are ARCA biopharma's headquarters?

ARCA biopharma is headquartered at 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020.

How can I contact ARCA biopharma?

ARCA biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at (720) 940-2200, via email at [email protected], or via fax at 720-208-9261.


This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.